VERA — Vera Therapeutics, Inc. stock price, charts and financials

QT51Vera Therapeutics, Inc.

Vera Therapeutics, Inc. (NASDAQ: VERA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
34.00
-0.27-0.79%
OverviewShort InterestFilings
VERAQT51Vera Therapeutics, Inc.·NASDAQ
34.00-0.79%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
HRMY-1.68%$42.02MLYS+0.14%$28.02VRDN+0.32%$22.00PHVS-4.29%$36.37CLDX-1.90%$38.24BEAM+1.14%$24.95IMNM+0.17%$23.97NAMS+2.55%$22.49
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand71.78MPerf Week-3.00%
Market Cap2.45BForward P/E-EPS next Y-4.43Insider Trans-0.62%Shs Float58.51MPerf Month5.33%
Enterprise Value2.02BPEG-EPS next Q-1.61Inst Own-Short Float33.96%Perf Quarter-3.11%
Income-300.00MP/S0.00EPS this Y-Inst Trans-Short Ratio9.50Perf Half Y-17.81%
Sales0.00P/B5.98EPS next Y29.20%ROA-75.40%Short Interest19.87MPerf YTD-32.86%
Book/sh5.68P/C4.89EPS next 5Y-ROE-84.13%52W High56.05 -39.34%Perf Year38.55%
Cash/sh6.95P/FCF-EPS past 3/5Y-ROIC-85.78%52W Low23.05 47.51%Perf 3Y101.90%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility8.79% 5.83%Perf 5Y30.12%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-113.09%Oper. Margin0.00%ATR (14)2.14Perf 10Y-
Dividend Ex-Date-Quick Ratio10.92Sales Y/Y TTM-Profit Margin0.00%RSI (14)49.96Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.92EPS Q/Q-26.67%SMA20-1.05%Beta0.98Target Price86.75
Payout0.00%Debt/Eq0.13Sales Q/Q-SMA50-1.13%Rel Volume1.69Prev Close34.27
Employees361LT Debt/Eq0.13EarningsNov 04SMA200-14.16%Avg Volume2.48MPrice34.00
IPO DateMay 14, 2021Option/ShortYes / YesEPS/Sales Surpr.3.54% -Net Debt/EBITDA-0.07Volume4,190,422Change-0.79%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-11-26ReiteratedRaymond JamesStrong Buy$78 → $84
Jul-08-26ReiteratedNeedham$125
Jul-08-26ReiteratedGuggenheimBuy$76
Jul-08-26ReiteratedHC Wainwright & Co.Buy$90 → $125
Jul-08-26ReiteratedWedbushNeutral$33 → $43
Jun-02-26ReiteratedJefferiesBuy$6.00 → $60
Jun-02-26ReiteratedGoldman SachsBuy$95 → $90
May-15-26ReiteratedEvercore ISI GroupOutperform$97 → $91
Mar-11-26UpgradeWolfe ResearchPeer Perform → Outperform
Dec-19-25ReiteratedGoldman SachsBuy$95
Latest News· Times ET
Sep-15-26
Sep-15-2609:51PM
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch NextYahoo
04:01PM
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
08:28AM
What's Going on With Vera Therapeutics Stock on Tuesday?benzinga.com
08:03AM
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Resultsbarrons.com
08:01AM
Why is Vera Therapeutics stock reversing its premarket gains?invezz.com
06:33AM
Vera Stock Slides Despite Positive Phase 3 Resultsschaeffersresearch.com
02:30AM
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathyglobenewswire.com
Sep-08-26
Sep-08-2607:47AM
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83Benzinga
Sep-04-26
Sep-04-2612:05PM
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Sep-01-26
Sep-01-2603:30AM
Vera Therapeutics to Participate at Upcoming Investor Conferencesglobenewswire.com
Aug-24-26
Aug-24-2606:22AM
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On MondayBenzinga
Aug-17-26
Aug-17-2610:20AM
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buyseekingalpha.com
Aug-11-26
Aug-11-2611:39PM
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERAdefenseworld.net
05:39AM
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34Benzinga
Aug-07-26
Aug-07-2612:05PM
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Company

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other1004124————
Research and Development21512678————
Other Operating Expense
000————
Operating Income-315-167-102————
Interest Expense884————
Unusual Expense
———————
Non-Operating Income (Expense)232310————
Net Income Before Taxes-300-152-96————
Income Taxes
000————
Consolidated Net Income-300-152-96————
Net Income From Continuing Operations-300-152-96————
Net Income-300-152-96————
EPS (Recurring)-4.66-2.75-2.25————
EPS (Basic, Before Extraordinaries)-4.66-2.75-2.25————
EPS (Diluted)-4.66-2.75-2.25————
EBITDA-292-144-92————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding645543————
Market Capitalization3,2412,326661————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$61.13$49.30$37.46$25.62$13.79● Close Price0.00M0.98M1.96M2.93M3.91MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fordyce MarshallPRESIDENT AND CEOSep 15 '26Sale37.0018,500684,500235,244Sep 17
Fordyce MarshallPRESIDENT AND CEOSep 15 '26Option Exercise2.9018,50053,591253,744Sep 17
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRSep 11 '26Option Exercise3.945,00019,69880,754Sep 14
Fordyce MarshallPRESIDENT AND CEOSep 02 '26Option Exercise2.9018,50053,591253,744Sep 04
Fordyce MarshallPRESIDENT AND CEOSep 02 '26Sale35.1218,500649,642235,244Sep 04
Fordyce MarshallPRESIDENT AND CEOJul 07 '26Sale42.3092,5003,912,374151,994Aug 12
Fordyce MarshallPRESIDENT AND CEOJul 07 '26Option Exercise2.9046,250133,977281,494Aug 12
Fordyce MarshallPRESIDENT AND CEOJun 23 '26Sale37.9337,0001,403,538198,244Aug 12
Fordyce MarshallPRESIDENT AND CEOJun 23 '26Option Exercise2.9018,50053,591253,744Aug 12
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Option Exercise2.9018,50053,591253,744Aug 12
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Sale36.7437,0001,359,494216,744Aug 12
Fordyce MarshallPRESIDENT AND CEOApr 14 '26Sale44.0522,9511,011,051235,244Apr 15
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRMar 13 '26Option Exercise3.9410,00039,39675,754Mar 16
Brenner RobertChief Medical OfficerFeb 23 '26Sale41.982,15190,30750,947Feb 25
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRFeb 23 '26Sale41.983,117130,86464,722Feb 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.